Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy UroGen Pharma stock

Own UroGen Pharma stock in just a few minutes.

UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 187 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in UroGen Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – URGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

UroGen Pharma share price

Use our graph to track the performance of URGN stocks over time.

UroGen Pharma shares at a glance

Information last updated 2021-03-10.
52-week range$13.12 - $30.89
50-day moving average $22.42
200-day moving average $21.30
Wall St. target price$41.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.89

Buy UroGen Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy UroGen Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

UroGen Pharma financials

Revenue TTM $3.8 million
Gross profit TTM $18,000
Return on assets TTM -45.25%
Return on equity TTM -82.63%
Profit margin 0%
Book value $5.46
Market capitalisation $429.5 million

TTM: trailing 12 months

Shorting UroGen Pharma shares

There are currently 2.8 million UroGen Pharma shares held short by investors – that's known as UroGen Pharma's "short interest". This figure is 1.5% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting UroGen Pharma shares can be evaluated.

UroGen Pharma's "short interest ratio" (SIR)

UroGen Pharma's "short interest ratio" (SIR) is the quantity of UroGen Pharma shares currently shorted divided by the average quantity of UroGen Pharma shares traded daily (recently around 176670.60702875). UroGen Pharma's SIR currently stands at 15.65. In other words for every 100,000 UroGen Pharma shares traded daily on the market, roughly 15650 shares are currently held short.

However UroGen Pharma's short interest can also be evaluated against the total number of UroGen Pharma shares, or, against the total number of tradable UroGen Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case UroGen Pharma's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 UroGen Pharma shares in existence, roughly 130 shares are currently held short) or 0.1554% of the tradable shares (for every 100,000 tradable UroGen Pharma shares, roughly 155 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against UroGen Pharma.

Find out more about how you can short UroGen Pharma stock.

UroGen Pharma share dividends

We're not expecting UroGen Pharma to pay a dividend over the next 12 months.

UroGen Pharma share price volatility

Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $13.1184 up to $30.89. A popular way to gauge a stock's volatility is its "beta".

URGN.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.2316. This would suggest that UroGen Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

UroGen Pharma overview

UroGen Pharma Ltd. , a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site